Exelixis, Inc. research snapshot
EXEL AI stock analysis currently reads Exelixis, Inc. as a commercial oncology company built on the cabozantinib franchise, with rising free cash flow, aggressive share repurchases, and a high-stakes pipeline handoff to zanzalintinib. At the July 12, 2026 data cutoff, EXEL closed near $56.50 on July 10 with a verified market capitalization of about $14.20 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$56.50
Market cap
$14.20 billion
AI score
71 / 100
Rating
Profitable oncology franchise with cabozantinib cash flow and zanzalintinib transition risk
Trend status
Uptrend above the 50-day and 200-day averages after a strong 52-week run
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Exelixis sells oncology medicines led by CABOMETYX (cabozantinib) in kidney, liver, thyroid, and neuroendocrine settings, with collaboration revenue and a next franchise candidate in zanzalintinib. | High |
| Moat | The moat comes from clinical evidence, label expansions, specialist relationships, combination data with PD-1/PD-L1 agents, and manufacturing plus commercial scale in GU and GI oncology. It narrows if competitors match outcomes or generics approach. | Medium |
| Management | CEO Michael Morrissey has led the company since 2010 through cabo commercialization, profitability, multi-year buybacks exceeding $2.5 billion, and a pipeline pivot to zanzalintinib. Capital allocation has favored repurchase over dividends. | Medium-high |
| Financial trend | FY2025 revenue reached $2.320 billion, GAAP net income $782.6 million, and free cash flow about $844 million. Q1 2026 total revenue was $610.8 million with cabozantinib U.S. net product revenue of $555.0 million. | High |
| Valuation | At $56.50, EXEL traded near 18.7x TTM EPS of $3.02, 7.4x book value of $7.63, and 15.5x TTM free cash flow per share of $3.65, with FCF yield about 6.5%. | High |
| Technical trend | Price sits above the StockAnalysis 50-day average near $51.19 and 200-day average near $44.60, with RSI near 63.5 and the 52-week range spanning about $33.76 to $57.57. | Medium |
| Risk level | Main risks are cabo concentration, LOE and competitive pressure, zanzalintinib regulatory and clinical outcomes, pricing and access pressure, and short interest near 12% of shares outstanding. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact price outcomes because biotech catalysts and oncology competition can dominate any earnings model. | High data confidence |
| Investment certainty | Medium certainty. EXEL has a real cash engine and a defined next product path, but the stock still needs zanza execution and durable cabo cash flows to support multi-year returns. | Medium |
EXEL AI stock forecast
The EXEL AI stock forecast uses scenario math around the $56.50 quote and TTM EPS of $3.02. The audited three-year framework produced a bullish area near $110, a base area near $65, and a bearish area near $33 before any major dilution, M&A, LOE shock, or binary trial or FDA events.
$105 to $115
More likely if cabo demand keeps growing in NET and core GU indications, zanzalintinib gains FDA approval in mCRC around the December 3, 2026 PDUFA window, additional pivotal STELLAR and partner trials de-risk the franchise, and investors assign a mid-20s growth PE.
$60 to $70
More likely if revenue grows high single digits to low double digits, margins stay strong, buybacks continue, zanza advances with mixed but workable data, and valuation stays near a mid-to-high teens earnings multiple.
$30 to $36
More likely if cabo growth stalls, LOE or competitive TKIs and IO combos cut share, zanzalintinib is delayed or rejected, short interest rises into weak catalysts, or the stock rerates toward a low-teens or sub-teens PE.
EXEL AI technical analysis
EXEL AI technical analysis is constructive as of the July 12, 2026 research cutoff using July 10 market data. StockAnalysis listed EXEL at $56.50, with the 50-day moving average near $51.19, the 200-day near $44.60, RSI near 63.52, and a 52-week gain of about 28%. Price is near the upper end of the 52-week band, so trend support matters more than fresh breakout confirmation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $56.50 | StockAnalysis close on July 10, 2026, used for market cap and valuation math. |
| Near support | $51 to $52 | The 50-day moving average near $51.19 is the first trend support zone after the recent run. |
| Secondary support | $44 to $45 | The 200-day moving average near $44.60 marks a deeper support band for the intermediate uptrend. |
| Moving averages | Bullish stack | Price above both the 50-day and 200-day averages favors a trend-following bias until those averages are lost. |
| Resistance | $57 to $58 | The recent 52-week high area near about $57.5 to $57.6 is the first overhead supply zone. |
| Higher resistance | $60 to $65 | A clean hold above the high-50s opens the path toward the base-case valuation band around $60 to $65. |
| Momentum | Positive but extended | RSI near 63.5 shows bullish momentum without extreme overbought readings, yet the stock is already close to 52-week highs. |
| Volume | Event-sensitive mid-cap biotech volume | Average volume near 2.8 million shares. Watch spikes around earnings, PDUFA news, STELLAR trial readouts, and competitive oncology headlines. |
| Volatility | Moderate beta with binary event risk | Five-year beta near 0.42 understates event risk around FDA actions and pivotal oncology data. |
| Invalidation | Close below $51, then $44.60 | A decisive close below the 50-day weakens the swing setup. A close below the 200-day would force a deeper trend review. |
EXEL AI trading strategy
The EXEL AI trading strategy is a rules-based framework for a profitable mid-cap oncology stock with product concentration, buyback support, and binary pipeline catalysts. It is not personal advice and should be paired with live quotes, filings, position sizing, and event calendars.
Watch for EXEL to hold above the $51 to $52 zone, stay above the 200-day average near $44.60, and attempt a controlled break of the $57 to $58 resistance area with confirming volume and no negative cabo or zanza headlines.
A close below $51 should invalidate the short-term long swing. A close below $44.60 should force a full review of product growth, pipeline news, and valuation assumptions.
If EXEL pulls back toward the 50-day average without a new clinical, competitive, or regulatory problem, compare the price move with cabo demand, cash and buybacks, and the zanza regulatory timeline.
Do not treat every pullback as mean reversion. Biotech support levels can fail quickly when PDUFA outcomes, trial readouts, or LOE narratives change.
Track cabozantinib U.S. net product revenue, total revenue mix, gross and operating margins, free cash flow, cash and marketable securities, debt, share-count reduction from repurchases, zanzalintinib NDA status, STELLAR and Merck collaboration trial timing, and short interest.
Reduce confidence if valuation depends mainly on a premium multiple rather than durable cabo cash flow, successful zanza progression, and continued capital returns.
Investment research summary
Exelixis turns kinase-inhibitor science, clinical development, regulatory labels, and specialist oncology commercial execution into recurring medicine revenue, primarily through cabozantinib and its next-generation candidate zanzalintinib.
The moat is strongest where clinical data, combination regimens, label breadth in RCC and NET, physician familiarity, and commercial infrastructure reinforce each other. It narrows if rivals match survival or progression outcomes, if payers force net-price pressure, or if LOE approaches faster than zanza scales.
The thesis fails if cabo growth slows earlier than expected, competition or generics erode the cash engine before zanza launches, the mCRC NDA or later pivotal trials disappoint, capital returns slow, or the multiple compresses while earnings growth is still cabo-dependent.
Management has converted a single-franchise biotech into a profitable commercial company with repeated buybacks. The next test is whether zanzalintinib becomes a second franchise while capital allocation remains disciplined across R&D, launch investment, and repurchases.
Oncology remains a long-duration growth field driven by combinations, biomarker segments, and oral targeted therapies. Exelixis sits in the multi-kinase inhibitor layer of GU and GI cancer care, where standards of care shift quickly as IO combos and next-generation TKIs evolve.
At roughly 18.7x TTM EPS and 15.5x FCF, EXEL is not priced like a pre-profit biotech, but it also does not embed unlimited zanza success. Margin of safety improves if cabo cash flows stay high and zanza de-risks. It shrinks if LOE or regulatory setbacks hit before earnings diversify.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| EXEL price | $56.50 close on July 10, 2026 | StockAnalysis statistics page | July 12, 2026 |
| Market capitalization | $14.20 billion, verified as $56.50 x 251.36 million shares (0.01% variance) | financial_rigor.py market cap verification and StockAnalysis | July 12, 2026 |
| Shares outstanding | 251.36 million | StockAnalysis and Morningstar cross-check | July 12, 2026 |
| FY2025 total revenue | $2.320 billion | Exelixis FY2025 earnings release and Macrotrends cross-check | July 12, 2026 |
| FY2025 GAAP net income and diluted EPS | $782.6 million net income and $2.78 diluted EPS | Exelixis FY2025 earnings release | July 12, 2026 |
| FY2025 cabozantinib U.S. net product revenues | $2.123 billion | Exelixis FY2025 earnings release | July 12, 2026 |
| FY2025 free cash flow | About $844 million | Macrotrends free cash flow series | July 12, 2026 |
| Q1 2026 total revenue and cabo product revenue | $610.8 million total revenue and $555.0 million cabozantinib franchise U.S. net product revenues | Exelixis Q1 2026 earnings release | July 12, 2026 |
| Q1 2026 GAAP diluted EPS and cash | $0.79 GAAP diluted EPS; cash and marketable securities about $1.4 billion at March 31, 2026 | Exelixis Q1 2026 earnings release and earnings call summary | July 12, 2026 |
| TTM valuation snapshot | TTM EPS $3.02, PE 18.7x, PB 7.4x, FCF per share $3.65, P/FCF 15.5x, FCF yield 6.46% | StockAnalysis statistics and financial_rigor.py valuation check | July 12, 2026 |
| Technical averages and momentum | 50-day MA $51.19, 200-day MA $44.60, RSI 63.52, 52-week change +28.21% | StockAnalysis statistics page | July 12, 2026 |
| Zanzalintinib regulatory catalyst | FDA accepted NDA for zanzalintinib plus atezolizumab in previously treated mCRC with PDUFA target action date December 3, 2026 | Exelixis Q1 2026 and ASCO 2026 pipeline updates | July 12, 2026 |
This EXEL AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if financial results, clinical data, regulation, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
